Lovastatin and simvastatin were observed to activate the integrated stress response (ISR; refs. 35, 36) and reduce MCL-1 (37, 38), promising properties for therapeutic candidates against multiple myeloma. The gene discussed is MCL1; the disease is plasma cell myeloma.